Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 5/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.54 |
| ▸ | VDR | P11473 | 8/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 4/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393099 | 0.89 | HDAC3 (0.66) | HDAC3HDAC6VDRHDAC1AR | |
| SCHEMBL3424308 | 0.87 | HDAC3 (0.60) | HDAC3HDAC6VDRHDAC1 | |
| SCHEMBL16183054 | 0.86 | HDAC3 (0.65) | HDAC3HDAC6VDRHDAC1AR | |
| SCHEMBL3394963 | 0.84 | HDAC3 (0.61) | HDAC3HDAC6VDRHDAC1 | |
| SCHEMBL13366655 | 0.84 | HDAC3 (0.61) | HDAC3HDAC6VDRHDAC1NR1H4 | |
| SCHEMBL13675118 | 0.84 | HDAC3 (0.63) | HDAC3HDAC6VDRAR | |
| SCHEMBL3395685 | 0.84 | HDAC3 (0.63) | HDAC3HDAC6VDRAR | |
| SCHEMBL13366700 | 0.83 | HDAC3 (0.81) | HDAC3HDAC6VDRHDAC1AR | |
| SCHEMBL3421448 | 0.82 | HDAC3 (0.48) | HDAC3HDAC6VDRNR1H4RXRB | |
| SCHEMBL13672892 | 0.82 | HDAC3 (0.58) | HDAC3HDAC6VDRHDAC1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601850-B2 | less hypercalcemic than 1a,25 dihydroxy vitamin D3; bone disorders, psoriasis | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1511740-B1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | LILLY CO ELI (US) | 2009-07-08 | — | — | EP | disclosed |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY | 2006-12-21 | — | — | US | disclosed |
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | ELI LILLY AND COMPANY PATENT DIVISON (US) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135484-A1 | Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | HDAC3 3386/4885HDAC6 4529/4885VDR 1/4885 |
| US-20060287536-A1 | Phenyl-thiophene type vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | HDAC3 2229/4885HDAC6 4626/4885VDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.